LRR protein RNH1 dampens the inflammasome activation and is associated with adverse clinical outcomes in COVID-19 patients
G. Bombaci, M. A. Sarangdhar, N. Andina, A. Tardivel, E. C.-W. Yu, G. M. Mackie, M. Pugh, V. B. Ozan, Y. Banz, T. Spinetti, C. Hirzel, E. Youd, J. C. Schefold, G. S. Taylor, A. Gazdhar, , R. Allam
This study identifies RNH1 as an inhibitor of inflammasome activation, showing its protective role in limiting inflammation and its association with worse outcomes in COVID-19.
bioRxiv · Apr 12, 2021 · PreprintImmunology